TOPLINE:
Switching from a boosted protease inhibitor (bPI)–based regimen to bictegravir plus emtricitabine plus tenofovir alafenamide (B/F/TAF) maintained virological suppression over 48 weeks in patients with HIV who had preexisting resistance to nucleoside reverse transcriptase inhibitors (NRTIs), however with increased adverse events.
METHODOLOGY:
- This phase 4 trial assessed the safety and efficacy of switching from a bPI-based regimen to B/F/TAF in virologically suppressed patients with HIV who had preexisting resistance to NRTIs.
- Overall, 72 patients (mean age, 55 years; 88.9% men) were randomly assigned to either continue a bPI-based regimen (delayed switch arm) or immediately switch to B/F/TAF (immediate switch arm).
- Participants in the immediate switch arm were followed-up for 48 weeks, whereas those in the…